Business Context and Reporting Period
Deep Medicine Acquisition Corp. (the registrant; Nasdaq: DMAQ and DMAQR) filed this Form 8-K on July 24, 2023, reporting events occurring July 21, 2023. The filing concerns its proposed business combination with TruGolf, Inc. and is not a quarterly or annual financial report.
Material Transaction Update
On July 21, 2023, Deep Medicine Acquisition Corp., DMAC Merger Sub Inc., Bright Vision Sponsor LLC, Christopher Jones and TruGolf, Inc. entered into an Amended and Restated Agreement and Plan of Merger. The agreement amended and restated the parties’ March 31, 2023 merger agreement.
- Contingent earnout shares will be issued after closing only if the specified milestones are achieved, rather than being issued at closing and placed in escrow subject to potential forfeiture.
- The common-stock price used to calculate merger consideration payable to TruGolf sellers is fixed at $10.00 per share, rather than being based on the redemption price paid to the SPAC’s public stockholders.
- The transaction remains subject to customary closing conditions, including stockholder approval and other conditions described in the merger agreement.
Financial Metrics and Liquidity
The filing does not provide current or prior-period revenue, profit, cash flow, margins, debt, liquidity, valuation, capitalization or other operating financial metrics. It also does not provide a financial forecast or a clear value for expected capital expenditures or future revenue.
Outlook, Risks and Unusual Items
The proposed business combination is not assured. Identified risks include failure to complete the transaction on a timely basis or at all, failure to satisfy closing conditions, termination of the merger agreement, potential legal proceedings, redemption levels among public stockholders, and uncertainty regarding TruGolf’s financial condition, liquidity, operating performance, products, market opportunity and expected benefits from the transaction.
The filing contains forward-looking statements regarding TruGolf, the proposed transaction and the prospective combined company. Actual results may differ materially, and neither party undertakes a general obligation to update these statements.
The company intends to file a Form S-4 registration statement containing a prospectus and proxy materials. Investors are directed to review those materials and subsequent SEC filings for complete transaction terms, financial statements, risk factors and information about the parties and solicitation participants.
Important Facts to Verify
- Whether the Form S-4 registration statement is filed and declared effective.
- Whether Deep Medicine Acquisition Corp. stockholders approve the business combination.
- Whether all other closing conditions are satisfied and the transaction closes.
- The final number and terms of merger consideration and any contingent earnout shares.
- Public-stockholder redemption levels and the resulting cash available to the combined company.
- TruGolf’s audited and pro forma financial statements, liquidity, debt and operating forecasts in subsequent filings.